Ondansetron Viatris

Ondondansetron, the active ingredient in Ondansetron Viatris, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: Helps control nausea during and after radiotherapy. - Post‑operative nausea and vomiting: Decreases the incidence of nausea and vomiting after surgical procedures. - Hyper‑emesis gravidarum (off‑label): May be considered when conventional anti‑emetics are ineffective. - Anticipatory nausea: Used in patients who develop nausea in anticipation of chemotherapy.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensations.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with intravenous use. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

When using Ondansetron, certain precautions should be considered to ensure safe and effective therapy.

- Cardiac monitoring: patients with known prolonged QT interval should be evaluated before use. - Drug interactions: review concomitant medications for potential serotonergic or QT‑prolonging effects. - Pregnancy: use only if clearly needed; discuss risks with a healthcare professional. - Breastfeeding: assess benefit‑risk ratio before continuation while nursing. - Renal/hepatic impairment: dose adjustment may be required; monitor organ function. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Apomatinib (c  …  ....  …  ....  …  … … … … … … … … … … … … … … … … … …)    …  …  … ...  … … … … … … … … … … … … … … … -  …  …  … … … … … … … … … … … … … … … … … … … …  … … … … … … … … … … … -   …  …  …  … …  … … …  … …  …  … … … … … … … … …  …  …  …  …

Moderate  …  ...  …  …  …  …  …  …  …  …  … -  …  …  …  -  …  …   -   … -    …   -    …